ASCO 2017- A phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in RRMM

Description: Background: Isatuximab (ISA) is an anti-CD38 monoclonal antibody, which kills tumor cells via multiple mechanisms. Here, we report preliminary data from the dose-escalation cohorts, and the first 3 patients (pts) of the expansion cohort, of a Phase Ib study of ISA plus Pom/Dex in pts with RRMM (NCT02283775).

Author(s): Joseph Mikhael, Paul G. Richardson, Saad Zafar Usmani, Noopur Raje, William Bensinger, Dheepak Kanagavel, Lei Gao, Samira Ziti-Ljajic, Kenneth Carl Anderson; Mayo Clinic, Phoenix, AZ; Dana-Farber Cancer Institute, Boston, MA; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; Massachusetts General Hospital, Boston, MA; Swedish Cancer Institute, Seattle, WA; Sanofi R&D, Vitry-Sur-Seine, France; Sanofi Oncology, Cambridge, MA; Sanofi, Vitry-Alfortville, France

Clinical trial information: NCT02283775
Shared By : InternationalMyelomaFoundation
Posted on : 08/15/17
Added : 2 years ago
Category : Multiple Myeloma